Vicinitas Therapeutics is a biotechnology company focused on targeted protein stabilizers known as Deubiquituinase Targeting Chimeras (DUBTACs). The company's mission is to use this proprietary technology to solve critical problems in human health by developing next-generation disease therapies against an entire class of previously inaccessible disease-causing proteins.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/28/22 | $65,000,000 | Series A |
A16z Berkeley Catalyst Fund Deerfield Management Company, L.P. DROIA Oncology Ventures GV The Mark Foundation for Cancer Research | undisclosed |
